z-logo
Premium
Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high‐risk follicular lymphoma due to severe haematological and infectious toxicity
Author(s) -
Cheah Chan Y.,
Nastoupil Loretta J.,
McLaughlin Peter,
Fanale Michelle A.,
Neelapu Sattva S.,
Fayad Luis E.,
Hagemeister Frederick B.,
Fowler Nathan H.
Publication year - 2016
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.13863
Subject(s) - medicine , bendamustine , rituximab , mitoxantrone , follicular lymphoma , adverse effect , tolerability , common terminology criteria for adverse events , fludarabine , neutropenia , oncology , surgery , lymphoma , gastroenterology , cyclophosphamide , chemotherapy

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom